Virtrial is using an award-winning virtual care platform to transform telehealth in the clinical research industry. Virtrial offers a patient management program that combines live video, text, and email for clinical trial sites to easily, efficiently, and conveniently address specific patient and/or study needs. The platform can be used on any device ((Mobile-Android and Apple or Desktop) at any site.
Virtrial was founded in 2018 by Mark Hanley, a research industry veteran and former CEO of Clinical Research Advantage(CRA) and Radiant Research. Joining Mark at Virtrial as VP of Clinical Operations is Kim Kundert. Kim has 20 years of research experience and worked under Marks leadership at CRA and Radiant.
Our vision at Virtrial is to revolutionize the clinical trial industry by making trials more patient centric. Thereby improving study enrollment, patient compliance and retention, ultimately bringing better medications to market more quickly.
Virtrial's secure, cloud-based platform affords pharmaceutical sponsors and CROs an opportunity to create and conduct clinical trials utilizing virtual visits. The advanced technology offers multiple modalities to engage patients and can be used on any device by any clinical trial site. Virtrial's model will incorporate a hybrid of in-person and virtual video visits that will alleviate some of the key pain points with clinical trials and enable patients to remain more actively engaged in the study. The Virtrial communication platform will automatically manage patient communication and touchpoints and provide a reporting platform for compliance.
Virtrial's advanced technology platform paired with its patient management program makes this combination of features a unique offering in the clinical trial space. Other technology companies may have pieces of what we can do but not all of it in one place.
By utilizing a hybrid model approach to trials, we can enhance current trials by replacing 25-50% of the visits with virtual video visits. We don't want to completely replace in-clinic visits, just maximize available resources to get results in an accurate, compliant and timely manner.
As there has been an industry shift to study chronic diseases due to the growing, aging population, FDA is now recommending longer post-approval trials be conducted to fully assess safety effects in a real-world setting. Hybrid virtual trials are a perfect platform for these post-approval trials as patients today keep their cell phone numbers for years. Contacting them virtually in 2-5 years will be possible.
Sponsors and CROs select trials they would like to incorporate virtual visits on. They contract with Virtrial to provide telehealth services for the trial. Virtrial then works with the network of research sites participating in the study to customize the study communications as well as timing and modality of the messaging to the patients.
The Virtrial app is downloaded onto the patients own phone (any type or iPad) at the first study visit in-clinic. Based on demographics, therapeutic area or time between in-person or virtual visits various engagement techniques can be implemented to maintain study compliance and retention.
Reporting and Analytics allows study sites to quickly identify non-compliant patients and quickly intervene to re-educate.
In 2016, the Tufts Center for the Study of Drug Development estimated average clinical trial costs across all three phases of development at roughly $340 million in out-of-pocket expenses, according to an article by Lisa LaMotta in Pharmadive. That study cited some of the tools that are optimizing clinical trials today: patient centricity, tapping into technology, wearable data, flexibility and automated site supplies. “Big pharmas and small biotechs alike are looking for innovative ways to improve trial outcomes and, in turn, lower trial costs — this means increasing the efficiency in which they recruit patients, monitoring more closely how drugs are supplied and being more flexible about trial design,” LaMotta concluded. Today, fewer than 5% of patients in the US participate in clinical trials, and they often don't stay. The average dropout rate is 30 percent. Nearly a fifth of trials are prematurely shut down due to participation shortfalls, according to a 2015 analysis, and many end up taking twice or even three times as long to complete as planned, experts say.
This trajectory can not continue. We must make trials more convenient for patients in order to overcome some of these challenges. Recent CISCRP research has suggested that the top five reasons for leaving a trial are "all associated with the inconvenience of having to go to a physical location to participate in the trial," says Ken Getz, founder of Center for information & Study on Clinical Research Participation (CISCRP).
While 87% of people want to participate in relevant clinical trials, 70% of them live more than 2 hours away from the nearest study center. 54% of the potential patients indicated home-based/virtual research visits would increase the likelihood of clinical trial participation. Early data on virtual clinical trials show there is only a 5% drop out rate.
Call us at 480-462-2222 or visit virtrial.com to request a demo today!